Results of selected studies of pretransplant salvage therapy for aggressive NHL.Response to second-line therapy and outcome according to intent-to-treat analysis.
| Regimen (reference) . | n . | Response Rate to Second-Line Chemotherapy . | Number Transplanted (%) . | Event-Free Survival . |
|---|---|---|---|---|
| * randomized trial—remaining patients randomized to continued DHAP therapy Abbreviations: mini-BEAM, carmustine, etoposide, cytarabine, melphalan; ICE, ifosfamide, carboplatin, etoposide; DHAP, dexamethasone, cytarabine, cisplatin; R-ICE, rituximab + ICE | ||||
| Mini-BEAM (19) | 102 | 43% | 38 (37%) | 22% at 3 years |
| ICE (20) | 163 | 66% | 96 (59%) | 35% at 3 years |
| DHAP (18, 25) | 215 | 58% | 55 (26%)* | 24% at 3 years |
| R-ICE (26) | 36 | 78% | 25 (69%) | 54% at 2 years* |
| Regimen (reference) . | n . | Response Rate to Second-Line Chemotherapy . | Number Transplanted (%) . | Event-Free Survival . |
|---|---|---|---|---|
| * randomized trial—remaining patients randomized to continued DHAP therapy Abbreviations: mini-BEAM, carmustine, etoposide, cytarabine, melphalan; ICE, ifosfamide, carboplatin, etoposide; DHAP, dexamethasone, cytarabine, cisplatin; R-ICE, rituximab + ICE | ||||
| Mini-BEAM (19) | 102 | 43% | 38 (37%) | 22% at 3 years |
| ICE (20) | 163 | 66% | 96 (59%) | 35% at 3 years |
| DHAP (18, 25) | 215 | 58% | 55 (26%)* | 24% at 3 years |
| R-ICE (26) | 36 | 78% | 25 (69%) | 54% at 2 years* |